The findings in this study demonstrated a new mechanism contributing to the development of PARPi resistance in HR-deficient ovarian cancer and showed the therapeutic potential of combining PARPi and ALDH1A1 inhibition in treating these patients. The gene discussed is ALDH1A1; the disease is ovarian carcinoma.